Pleiotropic anticoagulant functions of protein S, consequences for the clinical laboratory. Communication from the SSC of the ISTH

被引:7
|
作者
Brinkman, Herm Jan M. [1 ]
Ahnstrom, Josefin [2 ]
Castoldi, Elisabetta [3 ]
Dahlback, Bjorn [4 ]
Marlar, Richard A. [5 ]
机构
[1] Sanquin Res, Dept Mol & Cellular Hemostasis, Amsterdam, Netherlands
[2] Imperial Coll London, Ctr Haematol, London, England
[3] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Biochem, Maastricht, Netherlands
[4] Lund Univ, Dept Translat Med, Malmo, Sweden
[5] Univ New Mexico, Dept Pathol, TriCore Reference Labs, Albuquerque, NM 87131 USA
关键词
protein S; protein S deficiency; TISSUE FACTOR PATHWAY; THROMBIN-SENSITIVE REGION; AMINO-ACID-RESIDUES; FACTOR-X ACTIVATION; COFACTOR ACTIVITY; FACTOR VA; TFPI-ALPHA; INHIBITION; BINDING; DOMAIN;
D O I
10.1111/jth.15108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hereditary deficiencies of protein S (PS) increase the risk of thrombosis. However, assessing the plasma levels of PS is complicated by its manifold physiological interactions, while the large inter-individual variability makes it problematic to establish reliable cut-off values. PS has multiple physiological functions, with only two appearing to have significant anticoagulant properties: the activated protein C (APC) and tissue factor pathway inhibitor alpha (TFPI alpha) cofactor activities. Current clinical laboratory investigations for deficiency in PS function rely only on the APC-dependent activity. This communication presents an argument for reclassifying the qualitative PS deficiencies to differentiate the two major anticoagulant functions of PS. Reliable assays are necessary for accurate evaluation of PS function when making a specific diagnosis of PS deficiency based on the anticoagulant phenotype alone. This report emphasizes the pleiotropic anticoagulant functions of PS and presents evidence-based recommendations for their implementation in the clinical laboratory.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 37 条
  • [1] Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH
    Moore, Gary W.
    Van Cott, Elizabeth M.
    Cutler, Jacqueline A.
    Mitchell, Michael J.
    Adcock, Dorothy M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (09) : 1555 - 1561
  • [2] Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH
    Marlar, Richard A.
    Gausman, Jana N.
    Tsuda, Hiroko
    Rollins-Raval, Marian A.
    Brinkman, Herm Jan M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (01) : 68 - 74
  • [3] Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH
    Van Cott, Elizabeth M.
    Orlando, Christelle
    Moore, Gary W.
    Cooper, Peter C.
    Meijer, Piet
    Marlar, Richard
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (01) : 17 - 22
  • [4] Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH
    Devreese, K. M. J.
    Ortel, T. L.
    Pengo, V.
    de Laat, B.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (04) : 809 - 813
  • [5] Recommendations for the development of new anticoagulant drugs for pediatric use: communication from the SSC of the ISTH
    Male, C.
    Monagle, P.
    Chan, A. K. C.
    Young, G.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (03) : 481 - 484
  • [6] Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH
    Harenberg, J.
    Du, S.
    Weiss, C.
    Kraemer, R.
    Hoppensteadt, D.
    Walenga, J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (05) : 801 - 804
  • [7] Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH
    Dimichele, D. M.
    Lacroix-Desmazes, S.
    Peyvandi, F.
    Srivastava, A.
    Rosendaal, F. R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 876 - 879
  • [8] Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH
    Tripodi, A.
    de Laat, B.
    Wahl, D.
    Ageno, W.
    Cosmi, B.
    Crowther, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (11) : 2304 - 2307
  • [9] Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
    Ninivaggi, Marisa
    de Laat-Kremers, Romy
    Tripodi, Armando
    Wahl, Denis
    Zuily, Stephane
    Dargaud, Yesim
    Cate, Hugo ten
    Ignjatovic, Vera
    Devreese, Katrien M. J.
    de Laat, Bas
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (05) : 1372 - 1378
  • [10] Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH
    Frelinger, A. L., III
    Gachet, C.
    Mumford, A. D.
    Noris, P.
    Mezzano, D.
    Harrison, P.
    Gresele, P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (11) : 2341 - 2346